Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Curr Probl Cancer ; 45(6): 100755, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-33902928

RESUMO

OBJECTIVE: To evaluate the predictive value of a single nucleotide polymorphism (SNP) rs2686344 and squamous cell carcinoma antigen (SCCAg) levels in the clinical efficacy of neoadjuvant chemotherapy (NACT) for cervical cancer. METHODS: A total of 92 patients with stage IB2-IIIB carcinoma of the uterine cervix who received NACT treatment were enrolled. The relationship between the genotypes of SNP rs2686344 which is located on CAMKK2 on chromosome 12, SCCAg levels and the response to NACT was analyzed. The relationship between the SNP rs2686344 genotypes, SCCAg levels, the response to NACT and the five-year survival rate was evaluated. RESULTS: The effective group accounted for 84.85% in patients with low level (≤3.5 ng/mL) of post-treatment SCCAg (post-SCCAg), while the ineffective group accounted for 15.15%. The post-SCCAg levels and the genotypes of rs2686344 were significantly correlated with NACT response (P = 0.003, and P = 0.006). In patients with CC or CT genotype of SNP rs2686344, effective group accounted for 81.18%, while ineffective group accounted for 18.82%; For patients with TT genotype, effective response group accounted for 28.57%, ineffective group accounted for 71.43%. Post-SCCAg level >3.5 ng/mL and TT genotype of SNP rs2686344 showed as independent risk factors for NACT response in the multivariate analysis (P = 0.002, and P = 0.048). There was no significant difference in 5-year overall survival and 5-year disease-free survival between patients with different levels of post-SCCAg, or among different rs2686344 genotypes. CONCLUSION: The high level of post-SCCAg (>3.5 ng/mL) and TT genotype of rs2686344 may suggest a higher risk of poor response to NACT.


Assuntos
Antígenos de Neoplasias/efeitos dos fármacos , Antígenos de Neoplasias/genética , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Carcinoma de Células Escamosas/genética , Serpinas/efeitos dos fármacos , Serpinas/genética , Neoplasias do Colo do Útero/genética , Adulto , Idoso , Biomarcadores Tumorais , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/patologia , China/epidemiologia , Feminino , Genótipo , Humanos , Pessoa de Meia-Idade , Terapia Neoadjuvante/métodos , Polimorfismo de Nucleotídeo Único/genética , Fatores de Risco , Taxa de Sobrevida , Neoplasias do Colo do Útero/tratamento farmacológico , Neoplasias do Colo do Útero/mortalidade , Neoplasias do Colo do Útero/patologia
2.
Drug Discov Today ; 26(2): 442-454, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33259801

RESUMO

Serine protease inhibitors (serpins) are a large family of proteins that regulate and control crucial physiological processes, such as inflammation, coagulation, thrombosis and thrombolysis, and immune responses. The extraordinary impact that these proteins have on numerous crucial pathways makes them an attractive target for drug discovery. In this review, we discuss recent advances in research on small-molecule modulators of serpins, examine their mode of action, analyse the structural data from crystallised protein-ligand complexes, and highlight the potential obstacles and possible therapeutic perspectives. The application of in silico methods for rational drug discovery is also summarised. In addition, we stress the need for continued research in this field.


Assuntos
Descoberta de Drogas , Inibidores de Serina Proteinase/farmacologia , Serpinas/efeitos dos fármacos , Simulação por Computador , Cristalização , Humanos , Ligantes , Serpinas/metabolismo
3.
J Endocrinol ; 247(3): 283-294, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-33108345

RESUMO

Vaspin, visceral adipose tissue-derived serine protease inhibitor, plays important roles in inflammation, obesity, and glucose metabolism. Our recent research has shown the expression and role of vaspin in the function of ovarian follicles. However, whether vaspin regulates steroidogenesis and luteolysis in the corpus luteum (CL) is still unknown. The aim of this study was first to determine the expression of vaspin and its receptor GRP78 in porcine CL at the early, middle, and late stages of the luteal phase. Next, we investigated the hormonal regulation of vaspin levels in luteal cells in response to luteinizing hormone (LH), progesterone (P4), and prostaglandin PGE2 and PGF2α. Finally, we determined vaspin's direct impact on luteal cells steroidogenesis, luteolysis and kinases phosphorylation. Our results are the first to show higher vaspin/GRP78 expression in middle and late vs early stages; immunohistochemistry showed cytoplasmic vaspin/GRP78 localization in small and large luteal cells. In vitro, we found that LH, P4, PGE2, and PGF2α significantly decreased vaspin levels. Furthermore, vaspin stimulated steroidogenesis by the activation of the GRP78 receptor and protein kinase A (PKA). Also, vaspin increased the ratio of luteotropic PGE2 to luteolytic PGF2α secretion via GRP78 and mitogen-activated kinase (MAP3/1). Moreover, vaspin, in a dose-dependent manner, decreased GRP78 expression, while it, in a time-dependent manner, increased kinases PKA and MAPK3/1 phosphorylation. Taken together, we found that vaspin/GRP78 expression depends on the luteal phase stage and vaspin affects luteal cells endocrinology, indicating that vaspin is a new regulator of luteal cells steroidogenesis and CL formation.


Assuntos
Corpo Lúteo/metabolismo , Células Lúteas/metabolismo , Serpinas/metabolismo , Animais , Corpo Lúteo/efeitos dos fármacos , Dinoprosta/farmacologia , Dinoprostona/farmacologia , Feminino , Proteínas de Choque Térmico/metabolismo , Células Lúteas/efeitos dos fármacos , Hormônio Luteinizante/farmacologia , Luteólise/efeitos dos fármacos , Progesterona/farmacologia , Serpinas/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos , Suínos
4.
FASEB J ; 34(1): 619-630, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-31914706

RESUMO

Tannerella forsythia is a periodontopathogen that expresses miropin, a protease inhibitor in the serpin superfamily. In this study, we show that miropin is also a specific and efficient inhibitor of plasmin; thus, it represents the first proteinaceous plasmin inhibitor of prokaryotic origin described to date. Miropin inhibits plasmin through the formation of a stable covalent complex triggered by cleavage of the Lys368-Thr369 (P2-P1) reactive site bond with a stoichiometry of inhibition of 3.8 and an association rate constant (kass) of 3.3 × 105 M-1s-1. The inhibition of the fibrinolytic activity of plasmin was nearly as effective as that exerted by α2-antiplasmin. Miropin also acted in vivo by reducing blood loss in a mice tail bleeding assay. Importantly, intact T. forsythia cells or outer membrane vesicles, both of which carry surface-associated miropin, strongly inhibited plasmin. In intact bacterial cells, the antiplasmin activity of miropin protects envelope proteins from plasmin-mediated degradation. In summary, in the environment of periodontal pockets, which are bathed in gingival crevicular fluid consisting of 70% of blood plasma, an abundance of T. forsythia in the bacterial biofilm can cause local inhibition of fibrinolysis, which could have possible deleterious effects on the tooth-supporting structures of the periodontium.


Assuntos
Antifibrinolíticos/farmacologia , Fibrinólise/efeitos dos fármacos , Doenças Periodontais/tratamento farmacológico , Serpinas/efeitos dos fármacos , Animais , Bactérias/metabolismo , Domínio Catalítico , Feminino , Fibrinolisina/metabolismo , Fibrinolisina/farmacologia , Humanos , Camundongos Endogâmicos C57BL , Inibidores de Proteases/farmacologia , Serpinas/metabolismo
5.
Endocr J ; 67(1): 9-14, 2020 Jan 28.
Artigo em Inglês | MEDLINE | ID: mdl-31484851

RESUMO

Visceral adipose tissue-derived serine protease inhibitor (vaspin), initially identified in the visceral adipose tissue, is an adipokine that improves endoplasmic reticulum stress in obesity or insulin sensitivity and glucose tolerance. However, the transcriptional regulation of the hepatic vaspin gene remains elusive. We have previously shown that CCAAT-enhancer-binding protein α, a transcription factor of the basic leucine zipper class, positively regulates the vaspin gene. The present study aimed to investigate the nutritional or hormonal regulators of vaspin expression in the liver. For the fasting and refeeding study, mice in the fasting group were subjected to fasting for 24 h and then sacrificed. Mice in the refeeding group were subjected to fasting for 24 h and then refed with a 50% (w/w) sucrose/MF diet for further 24 h and then sacrificed. For the streptozotocin (STZ) study, STZ (50 mg/kg) was intraperitoneally injected into C57BL/6JJc1 mice for 5 d. Hepatic vaspin was repressed due to fasting for 24 h and was induced upon refeeding with a high-sucrose diet. In studies on liver-specific C/EBPα-deficient mice, C/EBPα was not involved in the induction of hepatic vaspin upon refeeding. In addition, the depletion of insulin by streptozotocin treatment markedly decreased hepatic vaspin expression. Finally, fasting-repressed vaspin expression in the liver was significantly increased by direct injection of insulin into fasting mice. In conclusion, our results suggest that insulin is a positive regulator of hepatic vaspin expression.


Assuntos
Adipocinas/genética , Diabetes Mellitus Experimental/genética , Jejum/metabolismo , Insulina/metabolismo , Fígado/metabolismo , Serpinas/genética , Adipocinas/metabolismo , Animais , Proteínas Estimuladoras de Ligação a CCAAT/genética , Diabetes Mellitus Experimental/metabolismo , Sacarose Alimentar , Regulação da Expressão Gênica , Hipoglicemiantes/farmacologia , Insulina/farmacologia , Gordura Intra-Abdominal/metabolismo , Fígado/efeitos dos fármacos , Camundongos , Camundongos Knockout , RNA Mensageiro/metabolismo , Serpinas/efeitos dos fármacos , Serpinas/metabolismo
6.
Exp Mol Med ; 49(12): e411, 2017 12 15.
Artigo em Inglês | MEDLINE | ID: mdl-29244789

RESUMO

Clinical expansion of mesenchymal stem cells (MSCs) is hampered by the lack of knowledge regarding how to prevent MSC apoptosis and promote their proliferation in serum-free medium. Our in vitro studies demonstrated that human umbilical cord MSCs (HUCMSCs) underwent apoptosis in the serum-free medium. When HUCMSCs were co-cultured with retinal pigment epithelial cells (ARPE19), however, HUCMSCs exhibited normal growth and morphology in serum-free medium. Their colony formation was promoted by the conditioned medium (CM) of ARPE19 cells on Matrigel. Proteomics analysis showed that pigment epithelium-derived factor (PEDF) was one of the most abundant extracellular proteins in the ARPE19 CM, whereas enzyme-linked immunosorbent assay confirmed that large amounts of PEDF was secreted from ARPE19 cells. Adding anti-PEDF-blocking antibodies to the co-culture of HUCMSCs with ARPE19 cells increased apoptosis of HUCMSCs. Conversely, treatment with PEDF significantly reduced apoptosis and increased proliferation of HUCMSCs in serum-free medium. PEDF was further demonstrated to exert this anti-apoptotic effect by inhibiting P53 expression to suppress caspase activation. In vivo studies demonstrated that co-injection of HUCMSCs with ARPE19 cells in immunocompromised NOD-SCID mice also increased survival and decreased apoptosis of HUCMSCs. PEDF also showed no negative effect on the mesoderm differentiation capability of HUCMSCs. In conclusion, this study is the first to demonstrate that PEDF promotes HUCMSC proliferation and protects them from apoptosis by reducing p53 expression in the serum-free medium. This study provides crucial information for clinical-scale expansion of HUCMSCs.


Assuntos
Diferenciação Celular/efeitos dos fármacos , Proteínas do Olho/efeitos dos fármacos , Células-Tronco Mesenquimais/citologia , Fatores de Crescimento Neural/efeitos dos fármacos , Serpinas/efeitos dos fármacos , Cordão Umbilical/citologia , Apoptose/efeitos dos fármacos , Linhagem Celular , Proliferação de Células/efeitos dos fármacos , Colágeno/farmacologia , Meios de Cultura Livres de Soro/farmacologia , Combinação de Medicamentos , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Humanos , Laminina/farmacologia , Células-Tronco Mesenquimais/efeitos dos fármacos , Mesoderma/citologia , Mesoderma/crescimento & desenvolvimento , Proteoglicanas/farmacologia , Epitélio Pigmentado da Retina/citologia , Epitélio Pigmentado da Retina/crescimento & desenvolvimento , Proteína Supressora de Tumor p53/genética
7.
J Ocul Pharmacol Ther ; 29(3): 363-5, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23046435

RESUMO

PURPOSE: To investigate the effect of intravitreal triamcinolone acetonide (TA) on aqueous humor levels of vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule 1 (sICAM-1), and pigment epithelium-derived factor (PEDF) in patients with central retinal vein occlusion (CRVO) and macular edema. METHODS: We measured VEGF, sICAM-1, and PEDF levels in aqueous humor samples from 2 eyes of 2 CRVO patients during injection of TA. RESULTS: In both patients, the VEGF and sICAM-1 levels in aqueous humor samples obtained during initial injection of TA were higher than at the time of reinjection. Conversely, the initial PEDF levels were lower than those at reinjection. CONCLUSIONS: Aqueous humor levels of VEGF and sICAM-1 were decreased by TA treatment in 2 CRVO patients, while PEDF was increased. Intravitreal TA could be an option for CRVO patients with a low PEDF level and/or moderate VEGF and sICAM-1 levels.


Assuntos
Glucocorticoides/uso terapêutico , Edema Macular/tratamento farmacológico , Oclusão da Veia Retiniana/tratamento farmacológico , Triancinolona Acetonida/uso terapêutico , Idoso , Humor Aquoso/efeitos dos fármacos , Humor Aquoso/metabolismo , Proteínas do Olho/efeitos dos fármacos , Proteínas do Olho/metabolismo , Feminino , Glucocorticoides/administração & dosagem , Humanos , Inflamação/tratamento farmacológico , Inflamação/patologia , Molécula 1 de Adesão Intercelular/efeitos dos fármacos , Molécula 1 de Adesão Intercelular/metabolismo , Injeções Intravítreas , Edema Macular/patologia , Masculino , Fatores de Crescimento Neural/efeitos dos fármacos , Fatores de Crescimento Neural/metabolismo , Oclusão da Veia Retiniana/patologia , Serpinas/efeitos dos fármacos , Serpinas/metabolismo , Triancinolona Acetonida/administração & dosagem , Fator A de Crescimento do Endotélio Vascular/efeitos dos fármacos , Fator A de Crescimento do Endotélio Vascular/metabolismo
8.
Curr Eye Res ; 37(11): 1025-9, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22906018

RESUMO

PURPOSE: To investigate the influence of lactate on expression of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) in rat retina. METHODS: Retinal explants from neonatal Sprague Dawley rats were incubated with media containing 10, 20, or 30 mM of lactic acid. The 10 mM group was used as a control. At 24 h after incubation, retinas were sectioned for light microscopy, and expressions of VEGF and PEDF measured by real-time polymerase chain reaction (RT-PCR) and Western blot analysis. RESULTS: The architecture of cultured retinas appeared to be intact. Compared with control, both RT-PCR and Western blot analysis showed that 30 mM of lactic acid significantly increased the levels of VEGF, but not PEDF. CONCLUSIONS: Stimulation of production of retinal VEGF by lactate is dependent on the concentration of lactate. Lactate has no effect on the expression of PEDF in rat retinal explants.


Assuntos
DNA/genética , Proteínas do Olho/genética , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Ácido Láctico/farmacologia , Fatores de Crescimento Neural/genética , Retina/metabolismo , Serpinas/genética , Fator A de Crescimento do Endotélio Vascular/genética , Animais , Animais Recém-Nascidos , Western Blotting , Proteínas do Olho/biossíntese , Proteínas do Olho/efeitos dos fármacos , Masculino , Fatores de Crescimento Neural/biossíntese , Fatores de Crescimento Neural/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Retina/efeitos dos fármacos , Retina/crescimento & desenvolvimento , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Serpinas/biossíntese , Serpinas/efeitos dos fármacos , Técnicas de Cultura de Tecidos , Fator A de Crescimento do Endotélio Vascular/biossíntese , Fator A de Crescimento do Endotélio Vascular/efeitos dos fármacos
9.
Br J Ophthalmol ; 95(9): 1309-15, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21719569

RESUMO

AIM: To explore the antiangiogenic property of isoliquiritigenin (ISL) on in vivo and in vitro models. DESIGN: Laboratory investigation. METHODS: The effect of ISL on angiogenesis development was investigated using ex ovo chick chorioallantoic membrane model. Its effect on pathological angiogenesis was examined by (1) silver nitrate cauterisation-induced corneal neovascularisation in BALB/c mice, followed by topical ISL (0.2-50 µM) and CD31 immunofluorescence of corneal blood vessels; (2) argon laser photocoagulation-induced choroidal neovascularisation in C57BL/6 mice, followed by intravitreal ISL (10-200 µM) and fundus fluorescein angiography and immunofluorescence with Griffonia simplicifolia isolectin-B4 (GSA I-B4); and (3) oxygen-induced retinopathy in C57BL/6J mice pups, followed by intravitreal ISL (1-100 µM) and GSA I-B4 immunofluorescence. The vascular area was quantified and analysed by one-way analysis of variance and Student t test. Expression of vascular endothelial growth factor (VEGF) and pigment-epithelium-derived factor in human umbilical vein endothelial cells was analysed by western blotting. RESULTS: Ex ovo chick chorioallantoic membrane assay showed that ISL dose-dependently suppressed VEGF-induced vessel growth. In vivo experiments illustrated that topical ISL alleviated corneal neovascularisation (IC(50)=7.14 µM, day 7) and intravitreal ISL reduced vessel leakage and GSA I-B4-positive vascular area in choroidal and retinal neovascularisation. ISL was found to dose-dependently suppress VEGF and induce pigment epithelium derived factor expression in cultured endothelial cells. CONCLUSION: Using various experimental models of ocular neovascularisation, the authors have demonstrated that ISL from licorice extract has an antiangiogenic effect. The authors' findings suggest that ISL may be a potential antiangiogenic molecule in the development of therapy for neovascularisation diseases.


Assuntos
Chalconas/farmacologia , Neovascularização de Coroide/tratamento farmacológico , Neovascularização da Córnea/tratamento farmacológico , Endotélio Vascular/efeitos dos fármacos , Glycyrrhiza , Neovascularização Retiniana/tratamento farmacológico , Animais , Animais Recém-Nascidos , Western Blotting , Células Cultivadas , Embrião de Galinha , Membrana Corioalantoide/efeitos dos fármacos , Membrana Corioalantoide/embriologia , Membrana Corioalantoide/metabolismo , Neovascularização de Coroide/metabolismo , Neovascularização de Coroide/patologia , Neovascularização da Córnea/metabolismo , Neovascularização da Córnea/patologia , Modelos Animais de Doenças , Progressão da Doença , Relação Dose-Resposta a Droga , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/metabolismo , Células Endoteliais/patologia , Endotélio Vascular/metabolismo , Endotélio Vascular/patologia , Inibidores Enzimáticos/farmacologia , Proteínas do Olho/biossíntese , Proteínas do Olho/efeitos dos fármacos , Feminino , Angiofluoresceinografia , Imunofluorescência , Fundo de Olho , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Fatores de Crescimento Neural/biossíntese , Fatores de Crescimento Neural/efeitos dos fármacos , Soluções Oftálmicas , Plantas , Neovascularização Retiniana/metabolismo , Neovascularização Retiniana/patologia , Serpinas/biossíntese , Serpinas/efeitos dos fármacos , Veias Umbilicais/citologia , Veias Umbilicais/efeitos dos fármacos , Veias Umbilicais/metabolismo , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Fator A de Crescimento do Endotélio Vascular/biossíntese
10.
FEBS Lett ; 583(19): 3165-70, 2009 Oct 06.
Artigo em Inglês | MEDLINE | ID: mdl-19729010

RESUMO

We studied the effect of acrolein, an alpha,beta-unsaturated aldehyde that causes adduct-modification of lysine, cysteine, and histidine residues, on antithrombin, a key anticoagulant serpin. Intrinsic fluorescence, functionality (anti-FXa and anti-IIa activity), heparin affinity and conformational features of plasma and purified antithrombin were evaluated. In vivo experiments were carried out in mice. Intrinsic fluorescence showed a two-step conformational change. Acrolein, even at low dose, impaired the anticoagulant function of purified antithrombin by affecting its heparin affinity. However, higher concentrations of acrolein and long incubations are required to cause mild functional effects on plasma antithrombin and mice.


Assuntos
Acroleína/farmacologia , Antitrombinas/efeitos dos fármacos , Animais , Antitrombinas/química , Fluorescência , Humanos , Camundongos , Conformação Proteica , Serpinas/química , Serpinas/efeitos dos fármacos
11.
Mol Vis ; 15: 45-59, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19145251

RESUMO

PURPOSE: The primate retina contains a specialized, cone-rich macula, which mediates high acuity and color vision. The spatial resolution provided by the neural retina at the macula is optimized by stereotyped retinal blood vessel and ganglion cell axon patterning, which radiate away from the macula and reduce shadowing of macular photoreceptors. However, the genes that mediate these specializations, and the reasons for the vulnerability of the macula to degenerative disease, remain obscure. The aim of this study was to identify novel genes that may influence retinal vascular patterning and definition of the foveal avascular area. METHODS: We used RNA from human fetal retinas at 19-20 weeks of gestation (WG; n=4) to measure differential gene expression in the macula, a region nasal to disc (nasal) and in the surrounding retina (surround) by hybridization to 12 GeneChip microarrays (HG-U133 Plus 2.0). The raw data was subjected to quality control assessment and preprocessing, using GC-RMA. We then used ANOVA analysis (Partek) Genomic Suite 6.3) and clustering (DAVID website) to identify the most highly represented genes clustered according to "biological process." The neural retina is fully differentiated at the macula at 19-20 WG, while neuronal progenitor cells are present throughout the rest of the retina. We therefore excluded genes associated with the cell cycle, and markers of differentiated neurons, from further analyses. Significantly regulated genes (p<0.01) were then identified in a second round of clustering according to molecular/reaction (KEGG) pathway. Genes of interest were verified by quantitative PCR (QRT-PCR), and 2 genes were localized by in situ hybridization. RESULTS: We generated two lists of differentially regulated genes: "macula versus surround" and "macula versus nasal." KEGG pathway clustering of the filtered gene lists identified 25 axon guidance-related genes that are differentially regulated in the macula. Furthermore, we found significant upregulation of three anti-angiogenic factors in the macula: pigment epithelium derived factor (PEDF), natriuretic peptide precurusor B (NPPB), and collagen type IValpha2. Differential expression of several members of the ephrin and semaphorin axon guidance gene families, PEDF, and NPPB was verified by QRT-PCR. Localization of PEDF and Eph-A6 mRNAs in sections of macaque retina shows expression of both genes concentrates in the ganglion cell layer (GCL) at the developing fovea, consistent with an involvement in definition of the foveal avascular area. CONCLUSIONS: Because the axons of macular ganglion cells exit the retina from around 8 WG, we suggest that the axon guidance genes highly expressed at the macula at 19-20 WG are also involved in vascular patterning, along with PEDF and NPPB. Localization of both PEDF and Eph-A6 mRNAs to the GCL of the developing fovea supports this idea. It is possible that specialization of the macular vessels, including definition of the foveal avascular area, is mediated by processes that piggyback on axon guidance mechanisms in effect earlier in development. These findings may be useful to understand the vulnerability of the macula to degeneration and to develop new therapeutic strategies to inhibit neovascularization.


Assuntos
Inibidores da Angiogênese/genética , Axônios/metabolismo , Perfilação da Expressão Gênica , Macula Lutea/embriologia , Macula Lutea/metabolismo , Adulto , Inibidores da Angiogênese/metabolismo , Animais , Proteínas do Olho/efeitos dos fármacos , Proteínas do Olho/metabolismo , Feto/metabolismo , Regulação da Expressão Gênica no Desenvolvimento , Humanos , Hibridização In Situ , Macaca , Proteínas de Membrana/genética , Proteínas de Membrana/metabolismo , Família Multigênica , Fatores de Crescimento Neural/efeitos dos fármacos , Fatores de Crescimento Neural/metabolismo , Análise de Sequência com Séries de Oligonucleotídeos , Controle de Qualidade , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Serpinas/efeitos dos fármacos , Serpinas/metabolismo
12.
J Endocrinol ; 200(2): 207-21, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19036760

RESUMO

Hypovitaminosis D is an important public health problem. Serum 25-hydroxyvitamin D (25-OHD) is now recognized as an independent predictor for cardiovascular and related diseases (CVD) as well as other chronic medical conditions. However, the biologic pathways through which these effects are mediated remain poorly understood. We hypothesized that exposing mesenchymal multipotent cells (MMCs) to the active form of vitamin D would increase the expression of selected antifibrotic factors that in turn would ameliorate the progression of chronic diseases. MMCs were primed with 5'-azacytidine to induce a fibrotic phenotype and then treated with active vitamin D (1,25D) or ethanol <0.1% as vehicle in a time course manner (30 min, 1, 5, and 24 h, and for 4 and 7 days). The addition of 1,25D to MMCs promotes: a) increased expression and nuclear translocation of the vitamin D receptor; b) decreased expression of TGFB1 and plasminogen activator inhibitor (SERPINE1), two well-known profibrotic factors; c) decreased expression of collagen I, III and other collagens isoforms; and d) increased expression of several antifibrotic factors such as BMP7 a TGFB1 antagonist, MMP8 a collagen breakdown inducer and follistatin, an inhibitor of the profibrotic factor myostatin. In conclusion, the addition of 1,25D to differentiated MMCs displays a decreased profibrotic signaling pathway and gene expression, leading to decrease in collagen deposition. This study highlights key mechanistic pathways through which vitamin D decreases fibrosis, and provides a rationale for studies to test vitamin D supplementation as a preventive and/or early treatment strategy for CVD and related fibrotic disorders.


Assuntos
Colágeno/efeitos dos fármacos , Fibrose/tratamento farmacológico , Expressão Gênica/efeitos dos fármacos , Vitamina D/farmacologia , Animais , Proteína Morfogenética Óssea 7/efeitos dos fármacos , Células Cultivadas , Etanol/farmacologia , Proteínas do Olho/efeitos dos fármacos , Folistatina/efeitos dos fármacos , Metaloproteinase 8 da Matriz/efeitos dos fármacos , Células-Tronco Mesenquimais , Camundongos , Camundongos Endogâmicos C3H , Fatores de Crescimento Neural/efeitos dos fármacos , Receptores de Calcitriol/efeitos dos fármacos , Serpinas/efeitos dos fármacos , Fatores de Tempo , Fator de Crescimento Transformador beta1/efeitos dos fármacos
13.
Clin Cancer Res ; 14(23): 7940-6, 2008 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-19047126

RESUMO

PURPOSE: 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a benzoquinone ansamycin antibiotic with antiproliferative activity in several mouse xenograft models, including prostate cancer models. A two-stage phase II study was conducted to assess the activity and toxicity profile of 17-AAG administered to patients with metastatic, hormone-refractory prostate cancer. EXPERIMENTAL DESIGN: Patients with at least one prior systemic therapy and a rising prostate-specific antigen (PSA) were eligible. Patients received 17-AAG at a dose of 300 mg/m2 i.v. weekly for 3 of 4 weeks. The primary objective was to assess the PSA response. Secondary objectives were to determine overall survival, to assess toxicity, and to measure interleukin-6, interleukin-8, and maspin levels and quality of life. RESULTS: Fifteen eligible patients were enrolled. The median age was 68 years and the median PSA was 261 ng/mL. Patients received 17-AAG for a median number of two cycles. Severe adverse events included grade 3 fatigue (four patients), grade 3 lymphopenia (two patients), and grade 3 back pain (two patients). The median PSA progression-free survival was 1.8 months (95% confidence interval, 1.3-3.4 months). The 6-month overall survival was 71% (95% confidence interval, 52-100%). CONCLUSIONS: 17-AAG did not show any activity with regard to PSA response. Due to insufficient PSA response, enrollment was stopped at the end of first stage per study design. The most significant severe toxicity was grade 3 fatigue. Further evaluation of 17-AAG at a dose of 300 mg/m2 i.v. weekly as a single agent in patients with metastatic, hormone-refractory prostate cancer who received at least one prior systemic therapy is not warranted.


Assuntos
Antineoplásicos/uso terapêutico , Benzoquinonas/uso terapêutico , Lactamas Macrocíclicas/uso terapêutico , Neoplasias da Próstata/tratamento farmacológico , Idoso , Resistencia a Medicamentos Antineoplásicos , Humanos , Imunoensaio , Interleucina-6/sangue , Interleucina-8/sangue , Interleucina-8/efeitos dos fármacos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Antígeno Prostático Específico/sangue , Antígeno Prostático Específico/efeitos dos fármacos , Neoplasias da Próstata/mortalidade , Qualidade de Vida , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Serpinas/biossíntese , Serpinas/efeitos dos fármacos
14.
Arterioscler Thromb Vasc Biol ; 28(4): 672-7, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18239154

RESUMO

OBJECTIVE: Serine protease inhibitors (serpin) play a central role in various pathological processes including coagulation, fibrinolysis, malignancy, and inflammation. Inhibition of serpins may prove therapeutic. As yet, however, only very few small molecule serpin inhibitors have been reported. For the first time, we apply a new approach of virtual screening to discover novel, orally active, small molecule serpin inhibitors and report their effectiveness. METHODS AND RESULTS: We focused on a clinically important serpin, plasminogen activator inhibitor-1 (PAI-1), whose crystal structure has been described. We identify novel, orally active molecules able to enter into the strand 4 position (s4A) of the A beta-sheet of PAI-I as a mock compound. In vitro they specifically inhibit the PAI-1 activity and enhance fibrinolysis activity. In vivo the most effective molecule (TM5007) inhibits coagulation in 2 models: a rat arteriovenous (AV) shunt model and a mouse model of ferric chloride-induced testicular artery thrombosis. It also prevents the fibrotic process initiated by bleomycin in mouse lung. CONCLUSIONS: The present study demonstrates beneficial in vitro and in vivo effects of novel PAI-1 inhibitors. Our methodology proves to be a useful tool to obtain effective inhibitors of serpin activity.


Assuntos
Anticoagulantes/farmacologia , Inibidor 1 de Ativador de Plasminogênio/fisiologia , Serpinas/efeitos dos fármacos , Animais , Anticoagulantes/química , Derivação Arteriovenosa Cirúrgica , Sítios de Ligação , Bleomicina/toxicidade , Coagulação Sanguínea/efeitos dos fármacos , Cloretos , Simulação por Computador , Avaliação Pré-Clínica de Medicamentos/métodos , Compostos Férricos/toxicidade , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Modelos Moleculares , Inibidor 1 de Ativador de Plasminogênio/química , Conformação Proteica , Fibrose Pulmonar/induzido quimicamente , Fibrose Pulmonar/patologia , Fibrose Pulmonar/prevenção & controle , Ratos , Serpina E2 , Serpinas/química , Serpinas/fisiologia , Testículo/irrigação sanguínea , Trombose/tratamento farmacológico , Interface Usuário-Computador
15.
J Int Med Res ; 35(3): 427-32, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17593873

RESUMO

Pigment epithelium-derived factor (PEDF) may have a protective role in atherosclerosis and is associated with the presence of components of the metabolic syndrome. Since oxidative stress has been postulated to play an important role in the pathogenesis of vascular injury in the metabolic syndrome, this study investigated the effects of hydrogen peroxide (H2O2) on PEDF in the immortalized human hepatocyte cell line OUMS-29. PEDF gene expression was measured using quantitative real-time reverse transcription-polymerase chain reaction and PEDF protein expression was analysed by Western blot. H2O2 upregulated PEDF mRNA levels and increased PEDF protein production in OUMS-29 cells in time- and dose-dependent manners. The anti-oxidant N-acetylcysteine significantly blocked H2O2-induced PEDF overexpression in OUMS-29 cells. These results suggest that hepatic PEDF levels may be elevated to counteract the effects of oxidative stress. H2O2-induced PEDF overproduction in the liver may act as a negative feedback system against vascular damage in the metabolic syndrome.


Assuntos
Proteínas do Olho/genética , Hepatócitos/efeitos dos fármacos , Peróxido de Hidrogênio/farmacologia , Fatores de Crescimento Neural/genética , Serpinas/genética , Linhagem Celular Transformada , Proteínas do Olho/efeitos dos fármacos , Proteínas do Olho/metabolismo , Regulação da Expressão Gênica/efeitos dos fármacos , Hepatócitos/metabolismo , Humanos , Fatores de Crescimento Neural/efeitos dos fármacos , Fatores de Crescimento Neural/metabolismo , Serpinas/efeitos dos fármacos , Serpinas/metabolismo
16.
FEBS J ; 273(11): 2540-52, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16704419

RESUMO

Mutations in neuroserpin and alpha1-antitrypsin cause these proteins to form ordered polymers that are retained within the endoplasmic reticulum of neurones and hepatocytes, respectively. The resulting inclusions underlie the dementia familial encephalopathy with neuroserpin inclusion bodies (FENIB) and Z alpha1-antitrypsin-associated cirrhosis. Polymers form by a sequential linkage between the reactive centre loop of one molecule and beta-sheet A of another, and strategies that block polymer formation are likely to be successful in treating the associated disease. We show here that glycerol, the sugar alcohol erythritol, the disaccharide trehalose and its breakdown product glucose reduce the rate of polymerization of wild-type neuroserpin and the Ser49Pro mutant that causes dementia. They also attenuate the polymerization of the Z variant of alpha1-antitrypsin. The effect on polymerization was apparent even when these agents had been removed from the buffer. None of these agents had any detectable effect on the structure or inhibitory activity of neuroserpin or alpha1-antitrypsin. These data demonstrate that sugar and alcohol molecules can reduce the polymerization of serpin mutants that cause disease, possibly by binding to and stabilizing beta-sheet A.


Assuntos
Carboidratos/uso terapêutico , Demência/tratamento farmacológico , Etanol/uso terapêutico , Cirrose Hepática/tratamento farmacológico , Serpinas/metabolismo , Dicroísmo Circular , Eritritol/farmacologia , Glucose/farmacologia , Glicerol/farmacologia , Modelos Moleculares , Neuropeptídeos/efeitos dos fármacos , Neuropeptídeos/metabolismo , Conformação Proteica , Estrutura Secundária de Proteína , Proteínas Recombinantes/efeitos dos fármacos , Proteínas Recombinantes/metabolismo , Serpinas/efeitos dos fármacos , Trealose/farmacologia , alfa 1-Antitripsina/química , alfa 1-Antitripsina/efeitos dos fármacos
17.
J Clin Oncol ; 24(11): 1729-44, 2006 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-16549823

RESUMO

PURPOSE: Insight into clinical response to platinum-based chemotherapy (PBC) in non-small-cell lung cancer (NSCLC). METHODS: Matched tumor and nontumor lung tissues from PBC-treated NSCLC patients (four nonresponders and four responders) and tumor tissue from an independent test set (four nonresponders and four responders), were profiled using microarrays. Lysosomal protease inhibitors SerpinB3 and cystatin C were highly correlated with clinical response and were further evaluated by immunohistochemistry in PBC-treated patients (36 prechemotherapy and 13 postchemotherapy). Investigation of the pathogenic and prognostic significance of SerpinB3 was performed in 251 primary tumors, with 64 regional lymph node pairs, from chemotherapy-naïve NSCLC patients using immunohistochemistry. RESULTS: Bioinformatic analyses of gene expression in the training set identified a gene set (n = 17) that separated all patients in the training and test sets (n = 16) according to response in hierarchical clustering. Transcriptome profiling revealed that SerpinB3 mRNA was highly correlated with degree of response (r = -0.978; P < .0001) and was a clear outlier (nonresponders:responders > 50-fold). SerpinB3 protein expression was correlated with clinical response in PBC-treated NSCLC patients (P = .045). Expression of SerpinB3 and cystatin C, relative to the target, protease cathepsin B, was independently predictive of response (odds ratio, 17.8; 95% CI, 2.0 to 162.4; P = .01), with an accuracy of 72%. High SerpinB3 expression levels, invariably associated with chemoresistance, had contrasting prognostic impact in untreated squamous cell carcinomas (hazard ratio [HR], 0.43; 95% CI, 0.18 to 0.93) or adenocarcinomas (HR, 2.09; 95% CI, 1.03 to 4.72). CONCLUSION: This provides the first comprehensive molecular characterization of clinical responsiveness to PBC in NSCLC and reveals the predictive and prognostic impact of two lysosomal protease inhibitors, potentially representing novel targets for NSCLC therapeutics.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/genética , Cistatinas/genética , Neoplasias Pulmonares/genética , Inibidores de Serina Proteinase/genética , Serpinas/efeitos dos fármacos , Idoso , Antineoplásicos/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/patologia , Cistatina C , Cistatinas/metabolismo , Feminino , Perfilação da Expressão Gênica , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Inibidores de Serina Proteinase/metabolismo , Serpinas/genética , Serpinas/metabolismo
18.
Thromb Haemost ; 93(3): 411-3, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15735788

RESUMO

To assess the potential roles of protein Z (PZ) and protein Z-dependent protease inhibitor (ZPI) in venous thrombosis, their plasma levels were measured in 426 individuals with venous thrombosis and 471 control individuals participating in the Leiden Thrombophilia Study. A relationship between the level of PZ or ZPI and venous thrombosis was not detected in the overall case-control study. PZ and ZPI circulate as a complex and their plasma levels are interdependent. Both PZ and ZPI are increased with oral contraceptive use and reduced with oral anticoagulant therapy.


Assuntos
Proteínas Sanguíneas/análise , Serpinas/sangue , Trombose Venosa/sangue , Adolescente , Adulto , Idoso , Proteínas Sanguíneas/efeitos dos fármacos , Proteínas Sanguíneas/fisiologia , Estudos de Casos e Controles , Anticoncepcionais Orais/farmacologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Serpinas/efeitos dos fármacos , Serpinas/fisiologia , Trombose Venosa/etiologia , Varfarina/farmacologia , Varfarina/uso terapêutico
19.
Thromb Res ; 115(4): 341-50, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15668194

RESUMO

Plasminogen activator inhibitor-1 (PAI-1) is a key negative regulator of the fibrinolytic system. In animal studies, inhibition of PAI-1 activity prevents arterial and venous thrombosis, indicating that PAI-1 inhibitors may be used as a new class of antithrombotics. In this study, we characterize a small molecule PAI-1 inhibitor, ZK4044, which was identified by high throughput screening and chemically optimized. In a chromogenic substrate-based urokinse (uPA)/PAI-1 assay and a tissue-type plasminogen activator (tPA)-mediated clot lysis assay, ZK4044 inhibited human PAI-1 activity with IC50 values of 644+/-255 and 100+/-90 nM, respectively. ZK4044 had no detectable inhibitory activity toward other serpins such as antithrombin III, alpha1-antitrypsin and alpha2-antiplasmin, indicating that ZK4044 is a specific PAI-1 inhibitor. ZK4044 was shown to bind directly to PAI-1 and prevent the binding of PAI-1 to tPA in a dose-dependent manner in surface plasmon resonance Biacore-based experiments. ZK4044 also prevented PAI-1/tPA complex formation, as analyzed by SDS/PAGE. ZK4044 had little effect on elastase-mediated cleavage of active PAI-1, indicating that the primary mode of action of ZK4044 is most likely to directly block the PAI-1/tPA interaction rather than to convert active PAI-1 to latent PAI-1. In the chromogenic substrate-based uPA/PAI-1 assay, ZK4044 was approximately 2-fold less potent against a mutant PAI-1 (14B-1), which contains four mutations at N150H, K154T, Q319L and M354I, compared with wild-type PAI-1, suggesting that the ZK4044 binding site on the surface of PAI-1 is close to these mutant residues. Together, our data show that ZK4044 represents a new class of small molecule PAI-1 inhibitors with anti-thrombotic potential.


Assuntos
Compostos de Anilina/farmacologia , Benzoatos/farmacologia , Fatores de Coagulação Sanguínea/antagonistas & inibidores , Fibrinolíticos/farmacologia , Inibidor 1 de Ativador de Plasminogênio/metabolismo , Compostos de Anilina/química , Animais , Benzoatos/química , Avaliação Pré-Clínica de Medicamentos , Fibrinolíticos/química , Humanos , Técnicas In Vitro , Cinética , Mutação , Inibidor 1 de Ativador de Plasminogênio/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Serpinas/efeitos dos fármacos , Serpinas/metabolismo , Ressonância de Plasmônio de Superfície , Ativador de Plasminogênio Tecidual/metabolismo
20.
Skin Pharmacol Physiol ; 17(6): 304-9, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15528961

RESUMO

Basal cell adhesion molecule (B-CAM) is strongly upregulated in epithelial skin cancer cells in vivo and in vitro. We have tested here whether B-CAM is (1) inversely associated with or (2) functionally involved in apoptosis. Towards this end, B-CAM expression was assessed in HaCaT transfectants overexpressing murine Bcl-2 and untransfected HaCaT cells exposed to various proapoptotic stimuli. In another series of experiments, we overexpressed B-CAM in HaCaT cells and different fibroblast lines, and stimulated various apoptotic pathways in the transfectants and control cells. In addition, apoptosis was assessed after an antibody-mediated B-CAM blockade. We could demonstrate that expression of B-CAM is inversely associated with the susceptibility of cells to apoptosis. However, overexpression or antibody- mediated inhibition of B-CAM had only limited functional effects on cellular apoptosis.


Assuntos
Apoptose/fisiologia , Carcinoma Basocelular/imunologia , Moléculas de Adesão Celular/fisiologia , Genes bcl-2/fisiologia , Neoplasias Cutâneas/imunologia , Aminoquinolinas/farmacologia , Animais , Anticorpos Monoclonais , Apoptose/efeitos dos fármacos , Moléculas de Adesão Celular/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Citometria de Fluxo , Humanos , Imiquimode , Camundongos , Serpinas/efeitos dos fármacos , Estaurosporina/farmacologia , Transfecção , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...